Combinatorial approach to cancer immunotherapy: Strength in numbers

Journal of Leukocyte Biology

Volumn 100, Issue 2, 2016, Pages 275-290

  Vilgelm, Anna E ^a,b   Johnson, Douglas B ^c   Richmond, Ann ^a,b  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Immune checkpoints; Immunogenic cell death; Melanoma; Senescence

Indexed keywords

AVELUMAB; BCG VACCINE; BMS 986016; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DABRAFENIB; EPACADOSTAT; ERLOTINIB; GEFITINIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMMUNOMODULATING AGENT; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; IPILIMUMAB; LAG 525; MBG 453; MEDI 6383; MEDI 6469; NIVOLUMAB; ONCOLYTIC VIRUS; PEMBROLIZUMAB; PF 05082566; PIDILIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; TALIMOGENE LAHERPAREPVEC; TICILIMUMAB; TRAMETINIB; TUMOR VACCINE; UNCLASSIFIED DRUG; URELUMAB; VARLILUMAB; VIAGENPUMATUCEL L; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER IMMUNOTHERAPY; DRUG POTENTIATION; DRUG TARGETING; EPIGENETICS; HUMAN; IMMUNOGENICITY; MOLECULAR MECHANICS; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; NEOPLASMS;

EID: 84980378048     PISSN: 07415400     EISSN: 19383673     Source Type: Journal    
DOI: 10.1189/jlb.5RI0116-013RR     Document Type: Review

References (192)

1. Rudd, C. E., Taylor, A., Schneider, H. (2009) CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol. Rev. 229, 12-26.
2. Stamper, C. C., Zhang, Y., Tobin, J. F., Erbe, D. V., Ikemizu, S., Davis, S. J., Stahl, M. L., Seehra, J., Somers, W. S., Mosyak, L. (2001) Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses. Nature 410, 608-611.
3. Pentcheva-Hoang, T., Egen, J. G., Wojnoonski, K., Allison, J. P. (2004) B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity 21, 401-413.
4. Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., Sakaguchi, S. (2008) CTLA-4 control over Foxp3+ regulatory T cell function. Science 322, 271-275.
5. Leach, D. R., Krummel, M. F., Allison, J. P. (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734-1736.
6. Sharma, P., Allison, J. P. (2015) The future of immune checkpoint therapy. Science 348, 56-61.
7. Kvistborg, P., Philips, D., Kelderman, S., Hageman, L., Ottensmeier, C., Joseph-Pietras, D., Welters, M. J., van der Burg, S., Kapiteijn, E., Michielin, O., Romano, E., Linnemann, C., Speiser, D., Blank, C., Haanen, J. B., Schumacher, T. N. (2014) Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci. Transl. Med. 6, 254ra128.
8. Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., Peggs, K. S., Ravetch, J. V., Allison, J. P., Quezada, S. A. (2013) Fcdependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 210, 1695-1710.
9. Hodi, F. S., O’Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., Akerley, W., van den Eertwegh, A. J., Lutzky, J., Lorigan, P., Vaubel, J. M., Linette, G. P., Hogg, D., Ottensmeier, C. H., Lebbé, C., Peschel, C., Quirt, I., Clark, J. I., Wolchok, J. D., Weber, J. S., Tian, J., Yellin, M. J., Nichol, G. M., Hoos, A., Urba, W. J. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723.
10. Robert, C., Thomas, L., Bondarenko, I., O’Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J. F., Testori, A., Grob, J. J., Davidson, N., Richards, J., Maio, M., Hauschild, A., Miller, Jr., W. H., Gascon, P., Lotem, M., Harmankaya, K., Ibrahim, R., Francis, S., Chen, T. T., Humphrey, R., Hoos, A., Wolchok, J. D. (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517-2526.
11. Ribas, A., Kefford, R., Marshall, M. A., Punt, C. J., Haanen, J. B., Marmol, M., Garbe, C., Gogas, H., Schachter, J., Linette, G., Lorigan, P., Kendra, K. L., Maio, M., Trefzer, U., Smylie, M., McArthur, G. A., Dreno, B., Nathan, P. D., Mackiewicz, J., Kirkwood, J. M., Gomez-Navarro, J., Huang, B., Pavlov, D., Hauschild, A. (2013) Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J. Clin. Oncol. 31, 616-622.
12. Callahan, M. K., Wolchok, J. D. (2015) Clinical activity, toxicity, biomarkers, and future development of CTLA-4 checkpoint antagonists. Semin. Oncol. 42, 573-586.
13. Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., Hollmann, T. J., Bruggeman, C., Kannan, K., Li, Y., Elipenahli, C., Liu, C., Harbison, C. T., Wang, L., Ribas, A., Wolchok, J. D., Chan, T. A. (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189-2199.
14. Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., Utikal, J., Hassel, J. C., Weide, B., Kaehler, K. C., Loquai, C., Mohr, P., Gutzmer, R., Dummer, R., Gabriel, S., Wu, C. J., Schadendorf, D., Garraway, L. A. (2015) Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207-211.
15. Ku, G. Y., Yuan, J., Page, D. B., Schroeder, S. E., Panageas, K. S., Carvajal, R. D., Chapman, P. B., Schwartz, G. K., Allison, J. P., Wolchok, J. D. (2010) Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 116, 1767-1775.
16. Ng Tang, D., Shen, Y., Sun, J., Wen, S., Wolchok, J. D., Yuan, J., Allison, J. P., Sharma, P. (2013) Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol. Res. 1, 229-234.
17. Hannani, D., Vétizou, M., Enot, D., Rusakiewicz, S., Chaput, N., Klatzmann, D., Desbois, M., Jacquelot, N., Vimond, N., Chouaib, S., Mateus, C., Allison, J. P., Ribas, A., Wolchok, J. D., Yuan, J., Wong, P., Postow, M., Mackiewicz, A., Mackiewicz, J., Schadendorff, D., Jaeger, D., Zörnig, I., Hassel, J., Korman, A. J., Bahjat, K., Maio, M., Calabro, L., Teng, M. W., Smyth, M. J., Eggermont, A., Robert, C., Kroemer, G., Zitvogel, L. (2015) Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res. 25, 208-224.
18. Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., Horton, H. F., Fouser, L., Carter, L., Ling, V., Bowman, M. R., Carreno, B. M., Collins, M., Wood, C. R., Honjo, T. (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027-1034.
19. Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., Lennon, V. A., Celis, E., Chen, L. (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8, 793-800.
20. Teng, M. W., Ngiow, S. F., Ribas, A., Smyth, M. J. (2015) Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 75, 2139-2145.
21. Lipson, E. J., Forde, P. M., Hammers, H. J., Emens, L. A., Taube, J. M., Topalian, S. L. (2015) Antagonists of PD-1 and PD-L1 in cancer treatment. Semin. Oncol. 42, 587-600.
22. Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., Savage, K. J., Hernberg, M. M., Lebbé, C., Charles, J., Mihalcioiu, C., Chiarion-Sileni, V., Mauch, C., Cognetti, F., Arance, A., Schmidt, H., Schadendorf, D., Gogas, H., Lundgren-Eriksson, L., Horak, C., Sharkey, B., Waxman, I. M., Atkinson, V., Ascierto, P. A. (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320-330.
23. KEYNOTE-006 Investigators. (2015) Pembrolizumab versus Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 372, 2521-2532.
24. Ribas, A., Puzanov, I., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Hodi, F. S., Schachter, J., Pavlick, A. C., Lewis, K. D., Cranmer, L. D., Blank, C. U., O’Day, S. J., Ascierto, P. A., Salama, A. K., Margolin, K. A., Loquai, C., Eigentler, T. K., Gangadhar, T. C., Carlino, M. S., Agarwala, S. S., Moschos, S. J., Sosman, J. A., Goldinger, S. M., Shapira-Frommer, R., Gonzalez, R., Kirkwood, J. M., Wolchok, J. D., Eggermont, A., Li, X. N., Zhou, W., Zernhelt, A. M., Lis, J., Ebbinghaus, S., Kang, S. P., Daud, A. (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 16, 908-918.
25. Weber, J. S., D’Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N. I., Miller, Jr., W. H., Lao, C. D., Linette, G. P., Thomas, L., Lorigan, P., Grossmann, K. F., Hassel, J. C., Maio, M., Sznol, M., Ascierto, P. A., Mohr, P., Chmielowski, B., Bryce, A., Svane, I. M., Grob, J. J., Krackhardt, A. M., Horak, C., Lambert, A., Yang, A. S., Larkin, J. (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 16, 375-384.
26. Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., Leming, P. D., Spigel, D. R., Antonia, S. J., Horn, L., Drake, C. G., Pardoll, D. M., Chen, L., Sharfman, W. H., Anders, R. A., Taube, J. M., McMiller, T. L., Xu, H., Korman, A. J., Jure-Kunkel, M., Agrawal, S., McDonald, D., Kollia, G. D., Gupta, A., Wigginton, J. M., Sznol, M. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454.
27. Herbst, R. S., Soria, J. C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., Kohrt, H. E., Horn, L., Lawrence, D. P., Rost, S., Leabman, M., Xiao, Y., Mokatrin, A., Koeppen, H., Hegde, P. S., Mellman, I., Chen, D. S., Hodi, F. S. (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563-567.
28. Carbognin, L., Pilotto, S., Milella, M., Vaccaro, V., Brunelli, M., Caliò, A., Cuppone, F., Sperduti, I., Giannarelli, D., Chilosi, M., Bronte, V., Scarpa, A., Bria, E., Tortora, G. (2015) Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One 10, e0130142.
29. Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., Waterhouse, D., Ready, N., Gainor, J., Arén Frontera, O., Havel, L., Steins, M., Garassino, M. C., Aerts, J. G., Domine, M., Paz-Ares, L., Reck, M., Baudelet, C., Harbison, C. T., Lestini, B., Spigel, D. R. (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123-135.
30. Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Ferrucci, P. F., Smylie, M., Dummer, R., Hill, A. G., Haanen, J. B. A. G., Maio, M., McArthur, G. A., Yang, A., Rollin, L., Horak, C. E., Larkin, J. M. G., Hodi, F. S. (2015) Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). J. Clin. Oncol. 33 (Suppl; abs. LBA1).
31. CheckMate 025 Investigators. (2015) Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N. Engl. J. Med. 373, 1803-1813.
32. Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., West, A. N., Carmona, M., Kivork, C., Seja, E., Cherry, G., Gutierrez, A. J., Grogan, T. R., Mateus, C., Tomasic, G., Glaspy, J. A., Emerson, R. O., Robins, H., Pierce, R. H., Elashoff, D. A., Robert, C., Ribas, A. (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568-571.
33. Curran, M. A., Montalvo, W., Yagita, H., Allison, J. P. (2010) PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl. Acad. Sci. USA 107, 4275-4280.
34. Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R. A., Reed, K., Burke, M. M., Caldwell, A., Kronenberg, S. A., Agunwamba, B. U., Zhang, X., Lowy, I., Inzunza, H. D., Feely, W., Horak, C. E., Hong, Q., Korman, A. J., Wigginton, J. M., Gupta, A., Sznol, M. (2013) Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122-133.
35. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., Ferrucci, P. F., Hill, A., Wagstaff, J., Carlino, M. S., Haanen, J. B., Maio, M., Marquez-Rodas, I., McArthur, G. A., Ascierto, P. A., Long, G. V., Callahan, M. K., Postow, M. A., Grossmann, K., Sznol, M., Dreno, B., Bastholt, L., Yang, A., Rollin, L. M., Horak, C., Hodi, F. S., Wolchok, J. D. (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23-34.
36. First immunotherapy combo approved for cancer. Cancer Discov. 5, 1228-1229.
37. Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., Shaheen, M., Ernstoff, M. S., Minor, D., Salama, A. K., Taylor, M., Ott, P. A., Rollin, L. M., Horak, C., Gagnier, P., Wolchok, J. D., Hodi, F. S. (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372, 2006-2017.
38. Monney, L., Sabatos, C. A., Gaglia, J. L., Ryu, A., Waldner, H., Chernova, T., Manning, S., Greenfield, E. A., Coyle, A. J., Sobel, R. A., Freeman, G. J., Kuchroo, V. K. (2002) Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415, 536-541.
39. Li, X., Hu, W., Zheng, X., Zhang, C., Du, P., Zheng, Z., Yang, Y., Wu, J., Ji, M., Jiang, J., Wu, C. (2015) Emerging immune checkpoints for cancer therapy. Acta Oncol. 54, 1706-1713.
40. Le Mercier, I., Lines, J. L., Noelle, R. J. (2015) Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators. Front. Immunol. 6, 418.
41. Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., Khoury, S. J., Zheng, X. X., Strom, T. B., Kuchroo, V. K. (2005) The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 6, 1245-1252.
42. Boenisch, O., D’Addio, F., Watanabe, T., Elyaman, W., Magee, C. N., Yeung, M. Y., Padera, R. F., Rodig, S. J., Murayama, T., Tanaka, K., Yuan, X., Ueno, T., Jurisch, A., Mfarrej, B., Akiba, H., Yagita, H., Najafian, N. (2010) TIM-3: a novel regulatory molecule of alloimmune activation. J. Immunol. 185, 5806-5819.
43. Chiba, S., Baghdadi, M., Akiba, H., Yoshiyama, H., Kinoshita, I., Dosaka-Akita, H., Fujioka, Y., Ohba, Y., Gorman, J. V., Colgan, J. D., Hirashima, M., Uede, T., Takaoka, A., Yagita, H., Jinushi, M. (2012) Tumorinfiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat. Immunol. 13, 832-842.
44. Anderson, A. C. (2014) Tim-3: an emerging target in the cancer immunotherapy landscape. Cancer Immunol. Res. 2, 393-398.
45. Jin, H. T., Anderson, A. C., Tan, W. G., West, E. E., Ha, S. J., Araki, K., Freeman, G. J., Kuchroo, V. K., Ahmed, R. (2010) Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc. Natl. Acad. Sci. USA 107, 14733-14738.
46. Zhou, Q., Munger, M. E., Veenstra, R. G., Weigel, B. J., Hirashima, M., Munn, D. H., Murphy, W. J., Azuma, M., Anderson, A. C., Kuchroo, V. K., Blazar, B. R. (2011) Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 117, 4501-4510.
47. Fourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Kuchroo, V., Zarour, H. M. (2010) Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J. Exp. Med. 207, 2175-2186.
48. Sakuishi, K., Ngiow, S. F., Sullivan, J. M., Teng, M. W., Kuchroo, V. K., Smyth, M. J., Anderson, A. C. (2013) TIM3(+)FOXP3(+) regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. OncoImmunology 2, e23849.
49. Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., Anderson, A. C. (2010) Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207, 2187-2194.
50. Ngiow, S. F., von Scheidt, B., Akiba, H., Yagita, H., Teng, M. W., Smyth, M. J. (2011) Anti-TIM3 antibody promotes T cell IFN-g-mediated antitumor immunity and suppresses established tumors. Cancer Res. 71, 3540-3551.
51. Triebel, F., Jitsukawa, S., Baixeras, E., Roman-Roman, S., Genevee, C., Viegas-Pequignot, E., Hercend, T. (1990) LAG-3, a novel lymphocyte activation gene closely related to CD4. J. Exp. Med. 171, 1393-1405.
52. Huard, B., Prigent, P., Tournier, M., Bruniquel, D., Triebel, F. (1995) CD4/major histocompatibility complex class II interaction analyzed with CD4-and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. Eur. J. Immunol. 25, 2718-2721.
53. Workman, C. J., Cauley, L. S., Kim, I. J., Blackman, M. A., Woodland, D. L., Vignali, D. A. A. (2004) Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo. J. Immunol. 172, 5450-5455.
54. Gandhi, M. K., Lambley, E., Duraiswamy, J., Dua, U., Smith, C., Elliott, S., Gill, D., Marlton, P., Seymour, J., Khanna, R. (2006) Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients. Blood 108, 2280-2289.
55. Durham, N. M., Nirschl, C. J., Jackson, C. M., Elias, J., Kochel, C. M., Anders, R. A., Drake, C. G. (2014) Lymphocyte activation gene 3 (LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo. PLoS One 9, e109080.
56. Huang, C. T., Workman, C. J., Flies, D., Pan, X., Marson, A. L., Zhou, G., Hipkiss, E. L., Ravi, S., Kowalski, J., Levitsky, H. I., Powell, J. D., Pardoll, D. M., Drake, C. G., Vignali, D. A. A. (2004) Role of LAG-3 in regulatory T cells. Immunity 21, 503-513.
57. Matsuzaki, J., Gnjatic, S., Mhawech-Fauceglia, P., Beck, A., Miller, A., Tsuji, T., Eppolito, C., Qian, F., Lele, S., Shrikant, P., Old, L. J., Odunsi, K. (2010) Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc. Natl. Acad. Sci. USA 107, 7875-7880.
58. Woo, S. R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., Tangsombatvisit, S., Grosso, J. F., Netto, G., Smeltzer, M. P., Chaux, A., Utz, P. J., Workman, C. J., Pardoll, D. M., Korman, A. J., Drake, C. G., Vignali, D. A. (2012) Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 72, 917-927.
59. Goding, S. R., Wilson, K. A., Xie, Y., Harris, K. M., Baxi, A., Akpinarli, A., Fulton, A., Tamada, K., Strome, S. E., Antony, P. A. (2013) Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. J. Immunol. 190, 4899-4909.
60. Yu, X., Harden, K., Gonzalez, L. C., Francesco, M., Chiang, E., Irving, B., Tom, I., Ivelja, S., Refino, C. J., Clark, H., Eaton, D., Grogan, J. L. (2009) The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat. Immunol. 10, 48-57.
61. Chauvin, J. M., Pagliano, O., Fourcade, J., Sun, Z., Wang, H., Sander, C., Kirkwood, J. M., Chen, T. H., Maurer, M., Korman, A. J., Zarour, H. M. (2015) TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients. J. Clin. Invest. 125, 2046-2058.
62. Kurtulus, S., Sakuishi, K., Ngiow, S. F., Joller, N., Tan, D. J., Teng, M. W., Smyth, M. J., Kuchroo, V. K., Anderson, A. C. (2015) TIGIT predominantly regulates the immune response via regulatory T cells. J. Clin. Invest. 125, 4053-4062.
63. Johnston, R. J., Comps-Agrar, L., Hackney, J., Yu, X., Huseni, M., Yang, Y., Park, S., Javinal, V., Chiu, H., Irving, B., Eaton, D. L., Grogan, J. L. (2014) The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell 26, 923-937.
64. Fourcade, J., Sun, Z., Pagliano, O., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Olive, D., Kuchroo, V., Zarour, H. M. (2012) CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res. 72, 887-896.
65. Haymaker, C. L., Wu, R. C., Ritthipichai, K., Bernatchez, C., Forget, M. A., Chen, J. Q., Liu, H., Wang, E., Marincola, F., Hwu, P., Radvanyi, L. G. (2015) BTLA marks a less-differentiated tumorinfiltrating lymphocyte subset in melanoma with enhanced survival properties. OncoImmunology 4, e1014246.
66. Chen, L. P., Flies, D. B. (2013) Molecular mechanisms of T cell costimulation and co-inhibition. Nat. Rev. Immunol. 13, 227-242.
67. Alegre, M. L., Frauwirth, K. A., Thompson, C. B. (2001) T-Cell regulation by CD28 and CTLA-4. Nat. Rev. Immunol. 1, 220-228.
68. Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., Panoskaltsis, N. (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355, 1018-1028.
69. Akiba, H., Nakano, H., Nishinaka, S., Shindo, M., Kobata, T., Atsuta, M., Morimoto, C., Ware, C. F., Malinin, N. L., Wallach, D., Yagita, H., Okumura, K. (1998) CD27, a member of the tumor necrosis factor receptor superfamily, activates NF-kappaB and stress-activated protein kinase/c-Jun N-terminal kinase via TRAF2, TRAF5, and NF-kappaBinducing kinase. J. Biol. Chem. 273, 13353-13358.
70. Ramakrishna, V., Sundarapandiyan, K., Zhao, B., Bylesjo, M., Marsh, H. C., Keler, T. (2015) Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab. J. Immunother. Cancer 3, 37.
71. Buchan, S. L., Manzo, T., Flutter, B., Rogel, A., Edwards, N., Zhang, L., Sivakumaran, S., Ghorashian, S., Carpenter, B., Bennett, C. L., Freeman, G. J., Sykes, M., Croft, M., Al-Shamkhani, A., Chakraverty, R. (2015) OX40-and CD27-mediated costimulation synergizes with anti-PD-L1 blockade by forcing exhausted CD8+ T cells to exit quiescence. J. Immunol. 194, 125-133.
72. Claus, C., Riether, C., Schürch, C., Matter, M. S., Hilmenyuk, T., Ochsenbein, A. F. (2012) CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth. Cancer Res. 72, 3664-3676.
73. Jacobs, J., Deschoolmeester, V., Zwaenepoel, K., Rolfo, C., Silence, K., Rottey, S., Lardon, F., Smits, E., Pauwels, P. (2015) CD70: an emerging target in cancer immunotherapy. Pharmacol. Ther. 155, 1-10.
74. Bartkowiak, T., Curran, M. A. (2015) 4-1BB agonists: multi-potent potentiators of tumor immunity. Front. Oncol. 5, 117.
75. Vinay, D. S., Kwon, B. S. (2011) 4-1BB signaling beyond T cells. Cell. Mol. Immunol. 8, 281-284.
76. Melero, I., Shuford, W. W., Newby, S. A., Aruffo, A., Ledbetter, J. A., Hellström, K. E., Mittler, R. S., Chen, L. (1997) Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med. 3, 682-685.
77. Adappa, N. D., Sung, C. K., Choi, B., Huang, T. G., Genden, E. M., Shin, E. J. (2008) The administration of IL-12/GM-CSF and Ig-4-1BB ligand markedly decreases murine floor of mouth squamous cell cancer. Otolaryngol. Head Neck Surg. 139, 442-448.
78. Houot, R., Goldstein, M. J., Kohrt, H. E., Myklebust, J. H., Alizadeh, A. A., Lin, J. T., Irish, J. M., Torchia, J. A., Kolstad, A., Chen, L., Levy, R. (2009) Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood 114, 3431-3438.
79. Gauttier, V., Judor, J. P., Le Guen, V., Cany, J., Ferry, N., Conchon, S. (2014) Agonistic anti-CD137 antibody treatment leads to antitumor response in mice with liver cancer. Int. J. Cancer 135, 2857-2867.
80. Li, B., Lin, J., Vanroey, M., Jure-Kunkel, M., Jooss, K. (2007) Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb. Clin. Immunol. 125, 76-87.
81. Tirapu, I., Arina, A., Mazzolini, G., Duarte, M., Alfaro, C., Feijoo, E., Qian, C., Chen, L., Prieto, J., Melero, I. (2004) Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens. Int. J. Cancer 110, 51-60.
82. Sznol, M., Hodi, F. S., Margolin, K., McDermott, D. F., Ernstoff, M. S., Kirkwood, J. M., Wojtaszek, C., Feltquate, D., Logan, T. (2008) Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). J. Clin. Oncol. 26 (Suppl 3007; abs.).
83. Ascierto, P. A., Simeone, E., Sznol, M., Fu, Y. X., Melero, I. (2010) Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin. Oncol. 37, 508-516.
84. Niu, L., Strahotin, S., Hewes, B., Zhang, B., Zhang, Y., Archer, D., Spencer, T., Dillehay, D., Kwon, B., Chen, L., Vella, A. T., Mittler, R. S. (2007) Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice. J. Immunol. 178, 4194-4213.
85. Dubrot, J., Milheiro, F., Alfaro, C., Palazón, A., Martinez-Forero, I., Perez-Gracia, J. L., Morales-Kastresana, A., Romero-Trevejo, J. L., Ochoa, M. C., Hervás-Stubbs, S., Prieto, J., Jure-Kunkel, M., Chen, L., Melero, I. (2010) Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ. Cancer Immunol. Immunother. 59, 1223-1233.
86. Segal, N. H., Gopal, A. K., Bhatia, S., Kohrt, H. E., Levy, R., Pishvalan, M. J., Houot, R., Bartlett, N., Nghlem, P., Kronenberg, S. A., Thali, A. D., Mugundu, G., Huang, B., Davis, C. (2014) A phase 1 study of PF-05082566 (auti-4-1BB) in patients with advanced cancer. J. Clin. Oncol. 32 (Suppl; abs. 3007).
87. Chen, S., Lee, L. F., Fisher, T. S., Jessen, B., Elliott, M., Evering, W., Logronio, K., Tu, G. H., Tsaparikos, K., Li, X., Wang, H., Ying, C., Xiong, M., VanArsdale, T., Lin, J. C. (2015) Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model. Cancer Immunol. Res. 3, 149-160.
88. Shindo, Y., Yoshimura, K., Kuramasu, A., Watanabe, Y., Ito, H., Kondo, T., Oga, A., Ito, H., Yoshino, S., Hazama, S., Tamada, K., Yagita, H., Oka, M. (2015) Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor. Anticancer Res. 35, 129-136.
89. Duraiswamy, J., Freeman, G. J., Coukos, G. (2013) Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res. 73, 6900-6912.
90. Kocak, E., Lute, K., Chang, X., May, Jr., K. F., Exten, K. R., Zhang, H., Abdessalam, S. F., Lehman, A. M., Jarjoura, D., Zheng, P., Liu, Y. (2006) Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res. 66, 7276-7284.
91. Curran, M. A., Kim, M., Montalvo, W., Al-Shamkhani, A., Allison, J. P. (2011) Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One 6, e19499.
92. Lane, P. (2000) Role of OX40 signals in coordinating CD4 T cell selection, migration, and cytokine differentiation in T helper (Th)1 and Th2 cells. J. Exp. Med. 191, 201-206.
93. Croft, M. (2010) Control of immunity by the TNFR-related molecule OX40 (CD134). Annu. Rev. Immunol. 28, 57-78.
94. Vetto, J. T., Lum, S., Morris, A., Sicotte, M., Davis, J., Lemon, M., Weinberg, A. (1997) Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers. Am. J. Surg. 174, 258-265.
95. Ramstad, T., Lawnicki, L., Vetto, J., Weinberg, A. (2000) Immunohistochemical analysis of primary breast tumors and tumordraining lymph nodes by means of the T-cell costimulatory molecule OX-40. Am. J. Surg. 179, 400-406.
96. Petty, J. K., He, K., Corless, C. L., Vetto, J. T., Weinberg, A. D. (2002) Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134). Am. J. Surg. 183, 512-518.
97. Ladányi, A., Somlai, B., Gilde, K., Fejös, Z., Gaudi, I., Tímár, J. (2004) T-Cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma. Clin. Cancer Res. 10, 521-530.
98. Marabelle, A., Kohrt, H., Sagiv-Barfi, I., Ajami, B., Axtell, R. C., Zhou, G., Rajapaksa, R., Green, M. R., Torchia, J., Brody, J., Luong, R., Rosenblum, M. D., Steinman, L., Levitsky, H. I., Tse, V., Levy, R. (2013) Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J. Clin. Invest. 123, 2447-2463.
99. Piconese, S., Valzasina, B., Colombo, M. P. (2008) OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J. Exp. Med. 205, 825-839.
100. Aspeslagh, S., Postel-Vinay, S., Rusakiewicz, S., Soria, J. C., Zitvogel, L., Marabelle, A. (2016) Rationale for anti-OX40 cancer immunotherapy. Eur. J. Cancer 52, 50-66.
101. Curti, B. D., Kovacsovics-Bankowski, M., Morris, N., Walker, E., Chisholm, L., Floyd, K., Walker, J., Gonzalez, I., Meeuwsen, T., Fox, B. A., Moudgil, T., Miller, W., Haley, D., Coffey, T., Fisher, B., Delanty-Miller, L., Rymarchyk, N., Kelly, T., Crocenzi, T., Bernstein, E., Sanborn, R., Urba, W. J., Weinberg, A. D. (2013) OX40 is a potent immunestimulating target in late-stage cancer patients. Cancer Res. 73, 7189-7198.
102. Redmond, W. L., Linch, S. N., Kasiewicz, M. J. (2014) Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity. Cancer Immunol. Res. 2, 142-153.
103. Houot, R., Levy, R. (2009) T-Cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood 113, 3546-3552.
104. Guo, Z., Wang, X., Cheng, D., Xia, Z., Luan, M., Zhang, S. (2014) PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer. PLoS One 9, e89350.
105. Nocentini, G., Giunchi, L., Ronchetti, S., Krausz, L. T., Bartoli, A., Moraca, R., Migliorati, G., Riccardi, C. (1997) A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis. Proc. Natl. Acad. Sci. USA 94, 6216-6221.
106. Tone, M., Tone, Y., Adams, E., Yates, S. F., Frewin, M. R., Cobbold, S. P., Waldmann, H. (2003) Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells. Proc. Natl. Acad. Sci. USA 100, 15059-15064.
107. McHugh, R. S., Whitters, M. J., Piccirillo, C. A., Young, D. A., Shevach, E. M., Collins, M., Byrne, M. C. (2002) CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 16, 311-323.
108. Shimizu, J., Yamazaki, S., Takahashi, T., Ishida, Y., Sakaguchi, S. (2002) Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol. 3, 135-142.
109. Zhou, P., L’italien, L., Hodges, D., Schebye, X. M. (2007) Pivotal roles of CD4+ effector T cells in mediating agonistic anti-GITR mAb-inducedimmune activation and tumor immunity in CT26 tumors. J. Immunol. 179, 7365-7375.
110. Cohen, A. D., Schaer, D. A., Liu, C., Li, Y., Hirschhorn-Cymmerman, D., Kim, S. C., Diab, A., Rizzuto, G., Duan, F., Perales, M. A., Merghoub, T., Houghton, A. N., Wolchok, J. D. (2010) Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS One 5, e10436.
111. Mitsui, J., Nishikawa, H., Muraoka, D., Wang, L., Noguchi, T., Sato, E., Kondo, S., Allison, J. P., Sakaguchi, S., Old, L. J., Kato, T., Shiku, H. (2010) Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Clin. Cancer Res. 16, 2781-2791.
112. Lu, L., Xu, X., Zhang, B., Zhang, R., Ji, H., Wang, X. (2014) Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs. J. Transl. Med. 12, 36.
113. Caux, C., Massacrier, C., Vanbervliet, B., Dubois, B., Van Kooten, C., Durand, I., Banchereau, J. (1994) Activation of human dendritic cells through CD40 cross-linking. J. Exp. Med. 180, 1263-1272.
114. Cella, M., Scheidegger, D., Palmer-Lehmann, K., Lane, P., Lanzavecchia, A., Alber, G. (1996) Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184, 747-752.
115. Zippelius, A., Schreiner, J., Herzig, P., Müller, P. (2015) Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment. Cancer Immunol. Res. 3, 236-244.
116. Melero, I., Lasarte, J. J. (2015) Genetic basis for clinical response to CTLA-4 blockade. N. Engl. J. Med. 372, 783.
117. Melero, I., Gaudernack, G., Gerritsen, W., Huber, C., Parmiani, G., Scholl, S., Thatcher, N., Wagstaff, J., Zielinski, C., Faulkner, I., Mellstedt, H. (2014) Therapeutic vaccines for cancer: an overview of clinical trials. Nat. Rev. Clin. Oncol. 11, 509-524.
118. Melief, C. J., van Hall, T., Arens, R., Ossendorp, F., van der Burg, S. H. (2015) Therapeutic cancer vaccines. J. Clin. Invest. 125, 3401-3412.
119. Kleponis, J., Skelton, R., Zheng, L. (2015) Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors. Cancer Biol. Med. 12, 201-208.
120. Morse, M. A., Lyerly, H. K. (2015) Checkpoint blockade in combination with cancer vaccines. Vaccine 33, 7377-7385.
121. Weber, J. S., Kudchadkar, R. R., Yu, B., Gallenstein, D., Horak, C. E., Inzunza, H. D., Zhao, X., Martinez, A. J., Wang, W., Gibney, G., Kroeger, J., Eysmans, C., Sarnaik, A. A., Chen, Y. A. (2013) Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or-naive melanoma. J. Clin. Oncol. 31, 4311-4318.
122. Löb, S., Königsrainer, A., Rammensee, H. G., Opelz, G., Terness, P. (2009) Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat. Rev. Cancer 9, 445-452.
123. Munn, D. H., Zhou, M., Attwood, J. T., Bondarev, I., Conway, S. J., Marshall, B., Brown, C., Mellor, A. L. (1998) Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281, 1191-1193.
124. Hwu, P., Du, M. X., Lapointe, R., Do, M., Taylor, M. W., Young, H. A. (2000) Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J. Immunol. 164, 3596-3599.
125. Mellor, A. L., Baban, B., Chandler, P., Marshall, B., Jhaver, K., Hansen, A., Koni, P. A., Iwashima, M., Munn, D. H. (2003) Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J. Immunol. 171, 1652-1655.
126. Yu, J., Wang, Y., Yan, F., Zhang, P., Li, H., Zhao, H., Yan, C., Yan, F., Ren, X. (2014) Noncanonical NF-kB activation mediates STAT3-stimulated IDO upregulation in myeloid-derived suppressor cells in breast cancer. J. Immunol. 193, 2574-2586.
127. Vacchelli, E., Aranda, F., Eggermont, A., Sautès-Fridman, C., Tartour, E., Kennedy, E. P., Platten, M., Zitvogel, L., Kroemer, G., Galluzzi, L. (2014) Trial watch: IDO inhibitors in cancer therapy. OncoImmunology 3, e957994.
128. Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., Van den Eynde, B. J. (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9, 1269-1274.
129. Muller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto-Ward, E., Prendergast, G. C. (2005) Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med. 11, 312-319.
130. Beatty, G. L., O’Dwyer, P. J., Clark, J., Shi, J. G., Newton, R. C., Schaub, R., Maleski, J., Leopold, L., Gajewski, T. (2013) Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies. J. Clin. Oncol. 31 (Suppl; abs. 3025).
131. Soliman, H. H., Antonia, S., Sullivan, D., Vanahanian, N., Link, C. (2009) Overcoming tumor antigen anergy in human malignancies using the novel indeolamine 2,3-dioxygenase (IDO) enzyme inhibitor, 1-methyl-D-tryptophan (1MT). J. Clin. Oncol. 27 (Suppl; abs. 3004).
132. Gibney, G., Hamid, O., Lutzky, J., Olszanski, A., Gangadhar, T., Gajewski, T., Chmielowski, B., Hanks, B., Boasberg, P., Zhao, Y., Newton, R., Bowman, J., Maleski, J., Leopold, L., Weber, J. S. (2015) Updated results from a phase 1/2 study of epacadostat (INCB024360) in combination with ipilimumab in patients with metastatic melanoma. Eur. J. Cancer 51 (Suppl 3), S106-S107.
133. Gangadhar, T. C., Hamid, O., Smith, D. C., Bauer, T. M., Wasser, J. S., Luke, J. J., Balmanoukian, A. S., Kaufman, D. R., Zhao, Y., Maleski, J., Leopold, L., Gajewski, T. F. (2015) Preliminary results from a phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers. J. Immunother. Cancer 3 (Suppl 2), O7.
134. Kroemer, G., Galluzzi, L., Kepp, O., Zitvogel, L. (2013) Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31, 51-72.
135. Garg, A. D., Martin, S., Golab, J., Agostinis, P. (2014) Danger signalling during cancer cell death: origins, plasticity and regulation. Cell Death Differ. 21, 26-38.
136. Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., Vandenabeele, P. (2012) Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer 12, 860-875.
137. Garg, A. D., Galluzzi, L., Apetoh, L., Baert, T., Birge, R. B., Bravo-San Pedro, J. M., Breckpot, K., Brough, D., Chaurio, R., Cirone, M., Coosemans, A., Coulie, P. G., De Ruysscher, D., Dini, L., de Witte, P., Dudek-Peric, A. M., Faggioni, A., Fucikova, J., Gaipl, U. S., Golab, J., Gougeon, M. L., Hamblin, M. R., Hemminki, A., Herrmann, M., Hodge, J. W., Kepp, O., Kroemer, G., Krysko, D. V., Land, W. G., Madeo, F., Manfredi, A. A., Mattarollo, S. R., Maueroder, C., Merendino, N., Multhoff, G., Pabst, T., Ricci, J. E., Riganti, C., Romano, E., Rufo, N., Smyth, M. J., Sonnemann, J., Spisek, R., Stagg, J., Vacchelli, E., Vandenabeele, P., Vandenberk, L., Van den Eynde, B. J., Van Gool, S., Velotti, F., Zitvogel, L., Agostinis, P. (2015) Molecular and translational classifications of DAMPs in immunogenic cell death. Front. Immunol. 6, 588.
138. Bezu, L., Gomes-de-Silva, L. C., Dewitte, H., Breckpot, K., Fucikova, J., Spisek, R., Galluzzi, L., Kepp, O., Kroemer, G. (2015) Combinatorial strategies for the induction of immunogenic cell death. Front. Immunol. 6, 187.
139. Zhang, Q., Raoof, M., Chen, Y., Sumi, Y., Sursal, T., Junger, W., Brohi, K., Itagaki, K., Hauser, C. J. (2010) Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 464, 104-107.
140. Fucikova, J., Moserova, I., Urbanova, L., Bezu, L., Kepp, O., Cremer, I., Salek, C., Strnad, P., Kroemer, G., Galluzzi, L., Spisek, R. (2015) Prognostic and predictive value of DAMPs and DAMP-associated processes in cancer. Front. Immunol. 6, 402.
141. Dewan, M. Z., Galloway, A. E., Kawashima, N., Dewyngaert, J. K., Babb, J. S., Formenti, S. C., Demaria, S. (2009) Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin. Cancer Res. 15, 5379-5388.
142. Demaria, S., Kawashima, N., Yang, A. M., Devitt, M. L., Babb, J. S., Allison, J. P., Formenti, S. C. (2005) Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin. Cancer Res. 11, 728-734.
143. Sharabi, A. B., Nirschl, C. J., Kochel, C. M., Nirschl, T. R., Francica, B. J., Velarde, E., Deweese, T. L., Drake, C. G. (2015) Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol. Res. 3, 345-355.
144. Zeng, J., See, A. P., Phallen, J., Jackson, C. M., Belcaid, Z., Ruzevick, J., Durham, N., Meyer, C., Harris, T. J., Albesiano, E., Pradilla, G., Ford, E., Wong, J., Hammers, H. J., Mathios, D., Tyler, B., Brem, H., Tran, P. T., Pardoll, D., Drake, C. G., Lim, M. (2013) Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int. J. Radiat. Oncol. Biol. Phys. 86, 343-349.
145. Deng, L., Liang, H., Burnette, B., Beckett, M., Darga, T., Weichselbaum, R. R., Fu, Y. X. (2014) Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest. 124, 687-695.
146. Dovedi, S. J., Adlard, A. L., Lipowska-Bhalla, G., McKenna, C., Jones, S., Cheadle, E. J., Stratford, I. J., Poon, E., Morrow, M., Stewart, R., Jones, H., Wilkinson, R. W., Honeychurch, J., Illidge, T. M. (2014) Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 74, 5458-5468.
147. Hiniker, S. M., Chen, D. S., Knox, S. J. (2012) Abscopal effect in a patient with melanoma. N. Engl. J. Med. 366, 2035; author reply 2035-2036.
148. Postow, M. A., Callahan, M. K., Barker, C. A., Yamada, Y., Yuan, J., Kitano, S., Mu, Z., Rasalan, T., Adamow, M., Ritter, E., Sedrak, C., Jungbluth, A. A., Chua, R., Yang, A. S., Roman, R. A., Rosner, S., Benson, B., Allison, J. P., Lesokhin, A. M., Gnjatic, S., Wolchok, J. D. (2012) Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366, 925-931.
149. Grimaldi, A. M., Simeone, E., Giannarelli, D., Muto, P., Falivene, S., Borzillo, V., Giugliano, F. M., Sandomenico, F., Petrillo, A., Curvietto, M., Esposito, A., Paone, M., Palla, M., Palmieri, G., Caracò, C., Ciliberto, G., Mozzillo, N., Ascierto, P. A. (2014) Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. OncoImmunology 3, e28780.
150. Chandra, R. A., Wilhite, T. J., Balboni, T. A., Alexander, B. M., Spektor, A., Ott, P. A., Ng, A. K., Hodi, F. S., Schoenfeld, J. D. (2015) A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. OncoImmunology 4, e1046028.
151. Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., Herati, R. S., Mansfield, K. D., Patsch, D., Amaravadi, R. K., Schuchter, L. M., Ishwaran, H., Mick, R., Pryma, D. A., Xu, X., Feldman, M. D., Gangadhar, T. C., Hahn, S. M., Wherry, E. J., Vonderheide, R. H., Minn, A. J. (2015) Radiation and dual checkpoint blockade activate nonredundant immune mechanisms in cancer. Nature 520, 373-377.
152. Madondo, M. T., Quinn, M., Plebanski, M. (2016) Low dose cyclophosphamide: mechanisms of T cell modulation. Cancer Treat. Rev. 42, 3-9.
153. Todo, T., Rabkin, S. D., Sundaresan, P., Wu, A., Meehan, K. R., Herscowitz, H. B., Martuza, R. L. (1999) Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replicationcompetent herpes simplex virus. Hum. Gene Ther. 10, 2741-2755.
154. Grekova, S. P., Raykov, Z., Zawatzky, R., Rommelaere, J., Koch, U. (2012) Activation of a glioma-specific immune response by oncolytic parvovirus Minute Virus of Mice infection. Cancer Gene Ther. 19, 468-475.
155. Koks, C. A., Garg, A. D., Ehrhardt, M., Riva, M., Vandenberk, L., Boon, L., De Vleeschouwer, S., Agostinis, P., Graf, N., Van Gool, S. W. (2015) Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death. Int. J. Cancer 136, E313-E325.
156. Zamarin, D., Holmgaard, R. B., Subudhi, S. K., Park, J. S., Mansour, M., Palese, P., Merghoub, T., Wolchok, J. D., Allison, J. P. (2014) Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci. Transl. Med. 6, 226ra32.
157. Andtbacka, R. H., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., Delman, K. A., Spitler, L. E., Puzanov, I., Agarwala, S. S., Milhem, M., Cranmer, L., Curti, B., Lewis, K., Ross, M., Guthrie, T., Linette, G. P., Daniels, G. A., Harrington, K., Middleton, M. R., Miller, Jr., W. H., Zager, J. S., Ye, Y., Yao, B., Li, A., Doleman, S., VanderWalde, A., Gansert, J., Coffin, R. S. (2015) Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 33, 2780-2788.
158. Puzanov, I., Milhem, M. M., Andtbacka, R. H. I., Minor, D. R., Hamid, O., Li, A., Chou, J., Kaufman, H. (2015) Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. J. Clin. Oncol. 33 (Suppl; abs. 9063).
159. Long, G. V., Dummer, R., Ribas, A., Puzanov, I., Michielin, O., Vanderwalde, A., Andtbacka, R. H. I., Cebon, J., Fernandez, E., Malvehy, J., Olszanski, A. J., Gajewski, T. F., Kirkwood, J. M., Gause, C., Chen, L., Kaufman, D. R., Chou, J., Hodi, F. S. (2015) 24LBA safety data from the phase 1b part of the MASTERKEY-265 study combining talimogene laherparepvec (T-VEC) and pembrolizumab for unresectable stage IIIBIV melanoma. Eur. J. Cancer 51 (Suppl 3), S722.
160. Covre, A., Coral, S., Di Giacomo, A. M., Taverna, P., Azab, M., Maio, M. (2015) Epigenetics meets immune checkpoints. Semin. Oncol. 42, 506-513.
161. Sigalotti, L., Fratta, E., Coral, S., Maio, M. (2014) Epigenetic drugs as immunomodulators for combination therapies in solid tumors. Pharmacol. Ther. 142, 339-350.
162. Coral, S., Sigalotti, L., Altomonte, M., Engelsberg, A., Colizzi, F., Cattarossi, I., Maraskovsky, E., Jager, E., Seliger, B., Maio, M. (2002) 5-aza-29-Deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin. Cancer Res. 8, 2690-2695.
163. Fonsatti, E., Nicolay, H. J., Sigalotti, L., Calabrò, L., Pezzani, L., Colizzi, F., Altomonte, M., Guidoboni, M., Marincola, F. M., Maio, M. (2007) Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-29-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clin. Cancer Res. 13, 3333-3338.
164. Adair, S. J., Hogan, K. T. (2009) Treatment of ovarian cancer cell lines with 5-aza-29-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules. Cancer Immunol. Immunother. 58, 589-601.
165. Magner, W. J., Kazim, A. L., Stewart, C., Romano, M. A., Catalano, G., Grande, C., Keiser, N., Santaniello, F., Tomasi, T. B. (2000) Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J. Immunol. 165, 7017-7024.
166. Mora-Garcia, M. D., Duenas-Gonzalez, A., Hernandez-Montes, J., De la Cruz-Hernandez, E., Perez-Cardenas, E., Weiss-Steider, B., Santiago-Osorio, E., Ortiz-Navarrete, V. F., Rosales, V. H., Cantu, D., Lizano-Soberon, M., Rojo-Aguilar, M. P., Monroy-Garcia, A. (2006) Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid. J. Transl. Med. 4, 55.
167. Armeanu, S., Bitzer, M., Lauer, U. M., Venturelli, S., Pathil, A., Krusch, M., Kaiser, S., Jobst, J., Smirnow, I., Wagner, A., Steinle, A., Salih, H. R. (2005) Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res. 65, 6321-6329.
168. Skov, S., Pedersen, M. T., Andresen, L., Straten, P. T., Woetmann, A., Odum, N. (2005) Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res. 65, 11136-11145.
169. West, A. C., Mattarollo, S. R., Shortt, J., Cluse, L. A., Christiansen, A. J., Smyth, M. J., Johnstone, R. W. (2013) An intact immune system is required for the anticancer activities of histone deacetylase inhibitors. Cancer Res. 73, 7265-7276.
170. Sonnemann, J., Gressmann, S., Becker, S., Wittig, S., Schmudde, M., Beck, J. F. (2010) The histone deacetylase inhibitor vorinostat induces calreticulin exposure in childhood brain tumour cells in vitro. Cancer Chemother. Pharmacol. 66, 611-616.
171. Kim, K., Skora, A. D., Li, Z., Liu, Q., Tam, A. J., Blosser, R. L., Diaz, Jr., L. A., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., Zhou, S. (2014) Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc. Natl. Acad. Sci. USA 111, 11774-11779.
172. Woods, D. M., Sodre, A. L., Villagra, A., Sarnaik, A., Sotomayor, E. M., Weber, J. (2015) HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade. Cancer Immunol. Res. 3, 1375-1385.
173. Covre, A., Coral, S., Nicolay, H., Parisi, G., Fazio, C., Colizzi, F., Fratta, E., Di Giacomo, A. M., Sigalotti, L., Natali, P. G., Maio, M. (2015) Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models. OncoImmunology 4, e1019978.
174. Kuilman, T., Peeper, D. S. (2009) Senescence-messaging secretome: SMS-ing cellular stress. Nat. Rev. Cancer 9, 81-94.
175. Coppé, J. P., Desprez, P. Y., Krtolica, A., Campisi, J. (2010) The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol. 5, 99-118.
176. Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., Lowe, S. W. (2007) Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656-660.
177. Kang, T. W., Yevsa, T., Woller, N., Hoenicke, L., Wuestefeld, T., Dauch, D., Hohmeyer, A., Gereke, M., Rudalska, R., Potapova, A., Iken, M., Vucur, M., Weiss, S., Heikenwalder, M., Khan, S., Gil, J., Bruder, D., Manns, M., Schirmacher, P., Tacke, F., Ott, M., Luedde, T., Longerich, T., Kubicka, S., Zender, L. (2011) Senescence surveillance of premalignant hepatocytes limits liver cancer development. Nature 479, 547-551.
178. Hoenicke, L., Zender, L. (2012) Immune surveillance of senescent cells—biological significance in cancer-and non-cancer pathologies. Carcinogenesis 33, 1123-1126.
179. Vilgelm, A., Richmond, A. (2015) Combined therapies that induce senescence and stabilize p53 block melanoma growth and prompt antitumor immune responses. OncoImmunology 4, e1009299.
180. Ewald, J. A., Desotelle, J. A., Wilding, G., Jarrard, D. F. (2010) Therapyinduced senescence in cancer. J. Natl. Cancer Inst. 102, 1536-1546.
181. Liu, Y., Hawkins, O. E., Su, Y., Vilgelm, A. E., Sobolik, T., Thu, Y. M., Kantrow, S., Splittgerber, R. C., Short, S., Amiri, K. I., Ecsedy, J. A., Sosman, J. A., Kelley, M. C., Richmond, A. (2013) Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-kB impairs this drug-induced senescence. EMBO Mol. Med. 5, 149-166.
182. Vilgelm, A. E., Johnson, C. A., Prasad, N., Yang, J., Chen, S.-C., Ayers, G. D., Pawlikowski, J. S., Raman, D., Sosman, J. A., Kelley, M., Ecsedy, J. A., Shyr, Y., Levy, S. E., Richmond, A. (2015) Connecting the dots: therapy-induced senescence and a tumor-suppressive immune microenvironment. J. Natl. Cancer Inst. 108, pii: djv406.
183. Liu, Y., Hawkins, O. E., Vilgelm, A. E., Pawlikowski, J. S., Ecsedy, J. A., Sosman, J. A., Kelley, M. C., Richmond, A. (2015) Combining an aurora kinase inhibitor and a death receptor ligand/agonist antibody triggers apoptosis in melanoma cells and prevents tumor growth in preclinical mouse models. Clin. Cancer Res. 21, 5338-5348.
184. Johnson, D. B., Sosman, J. A. (2015) Therapeutic advances and treatment options in metastatic melanoma. JAMA Oncol. 1, 380-386.
185. Long, G. V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J. J., Chiarion Sileni, V., Lebbe, C., Mandalà, M., Millward, M., Arance, A., Bondarenko, I., Haanen, J. B., Hansson, J., Utikal, J., Ferraresi, V., Kovalenko, N., Mohr, P., Probachai, V., Schadendorf, D., Nathan, P., Robert, C., Ribas, A., DeMarini, D. J., Irani, J. G., Casey, M., Ouellet, D., Martin, A. M., Le, N., Patel, K., Flaherty, K. (2014) Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N. Engl. J. Med. 371, 1877-1888.
186. Vanneman, M., Dranoff, G. (2012) Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer 12, 237-251.
187. Xu, M. M., Pu, Y., Zhang, Y., Fu, Y. X. (2016) The role of adaptive immunity in the efficacy of targeted cancer therapies. Trends Immunol. 37, 141-153.
188. Wargo, J. A., Cooper, Z. A., Flaherty, K. T. (2014) Universes collide: combining immunotherapy with targeted therapy for cancer. Cancer Discov. 4, 1377-1386.
189. Ribas, A., Hodi, F. S., Callahan, M., Konto, C., Wolchok, J. (2013) Hepatotoxicity with combination of vemurafenib and ipilimumab. N. Engl. J. Med. 368, 1365-1366.
190. Puzanov, I., Callahan, M. K., Linette, G. P., Patel, S. P., Luke, J. J., Sosman, J. A., Wolchok, J. D., Hamid, O., Minor, D. R., Orford, K. W., Hug, B. A., Ma, B., Matthys, G. M., Hoos, A. (2014) Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation positive unresectable or metastatic melanoma (MM). J. Clin. Oncol. 32 (Suppl; abs. 2511).
191. Ribas, A., Butler, M., Lutzky, J., Lawrence, D. P., Robert, C., Miller, W., Linette, G. P., Ascierto, P. A., Kuzel, T., Algazi, A. P., Postow, M. A., Nathan, P. D., Curti, B. D., Robbins, P. B., Li, X., Blake-Haskins, J. A., Gordon, M. S. (2015) Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. J. Clin. Oncol. 33 (Suppl; abs. 3003).
192. Smith, K. N., Housseau, F. (2015) An unexpected journey: how cancer immunotherapy has paved the way for an HIV-1 cure. Discov. Med. 19, 229-238.